23.07.2015 • News

Ardian Acquires ES and IM from DPx Holdings

Austrian private equity investor Ardian has acquired Exclusive Synthesis (ES) and Maleic Anhydride Intermediates & Specialties (IM) from Linz-based DPx Holdings for an undisclosed sum.

The assets held by the 51:49 joint venture of investor JLL Partners and Dutch chemical Group DSM were merged in 2013 from holdings of DSM Pharmaceutical Products and Patheon.

ES develops and produces chemical intermediates for agriculture and other industries. IM produces maleic anhydride, along with a large number of intermediates, derivatives and esters. Together they reported sales of some €200 million in 2014.

With Ardian’s support, management led by designated CEO Wolfgang Hillisch plans to “significantly strengthen” the units’ market position and expand through organic growth and acquisitions.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Top-Feature

most read